Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 7/2009

01.07.2009 | Original Article

FDG PET imaging of Ela1-myc mice reveals major biological differences between pancreatic acinar and ductal tumours

verfasst von: Ibane Abasolo, Judit Pujal, Rosa M. Rabanal, Anna Serafin, Pilar Navarro, Olga Millán, Francisco X. Real

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim was to evaluate FDG PET imaging in Ela1-myc mice, a pancreatic cancer model resulting in the development of tumours with either acinar or mixed acinar-ductal phenotype.

Methods

Transversal and longitudinal FDG PET studies were conducted; selected tissue samples were subjected to autoradiography and ex vivo organ counting. Glucose transporter and hexokinase mRNA expression was analysed by quantitative reverse transcription polymerase chain reaction (RT-PCR); Glut2 expression was analysed by immunohistochemistry.

Results

Transversal studies showed that mixed acinar-ductal tumours could be identified by FDG PET several weeks before they could be detected by hand palpation. Longitudinal studies revealed that ductal—but not acinar—tumours could be detected by FDG PET. Autoradiographic analysis confirmed that tumour areas with ductal differentiation incorporated more FDG than areas displaying acinar differentiation. Ex vivo radioactivity measurements showed that tumours of solely acinar phenotype incorporated more FDG than pancreata of non-transgenic littermates despite the fact that they did not yield positive PET images. To gain insight into the biological basis of the differential FDG uptake, glucose transporter and hexokinase transcript expression was studied in microdissected tumour areas enriched for acinar or ductal cells and validated using cell-specific markers. Glut2 and hexokinase I and II mRNA levels were up to 20-fold higher in ductal than in acinar tumours. Besides, Glut2 protein overexpression was found in ductal neoplastic cells but not in the surrounding stroma.

Conclusion

In Ela1-myc mice, ductal tumours incorporate significantly more FDG than acinar tumours. This difference likely results from differential expression of Glut2 and hexokinases. These findings reveal previously unreported biological differences between acinar and ductal pancreatic tumours.
Literatur
1.
Zurück zum Zitat DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999;117:1464–84.PubMedCrossRef DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999;117:1464–84.PubMedCrossRef
2.
Zurück zum Zitat Real FX. A “catastrophic hypothesis” for pancreas cancer progression. Gastroenterology 2003;124:1958–64.PubMedCrossRef Real FX. A “catastrophic hypothesis” for pancreas cancer progression. Gastroenterology 2003;124:1958–64.PubMedCrossRef
3.
Zurück zum Zitat Chin BB, Chang PP. Gastrointestinal malignancies evaluated with (18)F-fluoro-2-deoxyglucose positron emission tomography. Best Pract Res Clin Gastroenterol 2006;20:3–21.PubMedCrossRef Chin BB, Chang PP. Gastrointestinal malignancies evaluated with (18)F-fluoro-2-deoxyglucose positron emission tomography. Best Pract Res Clin Gastroenterol 2006;20:3–21.PubMedCrossRef
4.
Zurück zum Zitat Delbeke D, Pinson CW. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 2004;11:4–10.PubMedCrossRef Delbeke D, Pinson CW. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 2004;11:4–10.PubMedCrossRef
5.
Zurück zum Zitat Aguilar S, Corominas JM, Malats N, Pereira JA, Dufresne M, Real FX, et al. Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression. Am J Pathol 2004;165:1129–39.PubMed Aguilar S, Corominas JM, Malats N, Pereira JA, Dufresne M, Real FX, et al. Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression. Am J Pathol 2004;165:1129–39.PubMed
6.
Zurück zum Zitat Sandgren EP, Quaife CJ, Paulovich AG, Palmiter RD, Brinster RL. Pancreatic tumor pathogenesis reflects the causative genetic lesion. Proc Natl Acad Sci USA 1991;88:93–7.PubMedCrossRef Sandgren EP, Quaife CJ, Paulovich AG, Palmiter RD, Brinster RL. Pancreatic tumor pathogenesis reflects the causative genetic lesion. Proc Natl Acad Sci USA 1991;88:93–7.PubMedCrossRef
7.
Zurück zum Zitat Liao DJ, Wang Y, Wu J, Adsay NV, Grignon D, Khanani F, et al. Characterization of pancreatic lesions from MT-tgf alpha, Ela-myc and MT-tgf alpha/Ela-myc single and double transgenic mice. J Carcinog 2006;5:19.PubMedCrossRef Liao DJ, Wang Y, Wu J, Adsay NV, Grignon D, Khanani F, et al. Characterization of pancreatic lesions from MT-tgf alpha, Ela-myc and MT-tgf alpha/Ela-myc single and double transgenic mice. J Carcinog 2006;5:19.PubMedCrossRef
8.
Zurück zum Zitat Thorens B. Molecular and cellular physiology of Glut-2, a high-Km facilitated diffusion glucose transporter. Int Rev Cytol 1992;137:209–38.PubMedCrossRef Thorens B. Molecular and cellular physiology of Glut-2, a high-Km facilitated diffusion glucose transporter. Int Rev Cytol 1992;137:209–38.PubMedCrossRef
9.
Zurück zum Zitat Smith TAD. The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nucl Med Biol 2001;28:1–4.PubMedCrossRef Smith TAD. The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nucl Med Biol 2001;28:1–4.PubMedCrossRef
10.
Zurück zum Zitat Hernández-Muñoz I, Skoudy A, Real FX, Navarro P. Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution. Pancreatology 2008;8:462–9.PubMedCrossRef Hernández-Muñoz I, Skoudy A, Real FX, Navarro P. Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution. Pancreatology 2008;8:462–9.PubMedCrossRef
11.
Zurück zum Zitat Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Mazière B. FDG accumulation and tumor biology. Nucl Med Biol 1998;25:317–22.PubMedCrossRef Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Mazière B. FDG accumulation and tumor biology. Nucl Med Biol 1998;25:317–22.PubMedCrossRef
12.
Zurück zum Zitat Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (Glut) proteins in cancer. J Cell Physiol 2005;202:654–62.PubMedCrossRef Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (Glut) proteins in cancer. J Cell Physiol 2005;202:654–62.PubMedCrossRef
13.
Zurück zum Zitat Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 2000;57:170–8.PubMed Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 2000;57:170–8.PubMed
14.
Zurück zum Zitat Nakata B, Nishimura S, Ishikawa T, Ohira M, Nishino H, Kawabe J, et al. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol 2001;19:53–8.PubMed Nakata B, Nishimura S, Ishikawa T, Ohira M, Nishino H, Kawabe J, et al. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol 2001;19:53–8.PubMed
15.
Zurück zum Zitat Zimny M, Fass J, Bares R, Cremerius U, Sabri O, Buechin P, et al. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand J Gastroenterol 2000;35:883–8.PubMedCrossRef Zimny M, Fass J, Bares R, Cremerius U, Sabri O, Buechin P, et al. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand J Gastroenterol 2000;35:883–8.PubMedCrossRef
16.
Zurück zum Zitat Seitz U, Wagner M, Vogg AT, Glatting G, Neumaier B, Greten FR, et al. In vivo evaluation of 5-[(18)F]fluoro-2′-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model. Cancer Res 2001;61:3853–7.PubMed Seitz U, Wagner M, Vogg AT, Glatting G, Neumaier B, Greten FR, et al. In vivo evaluation of 5-[(18)F]fluoro-2′-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model. Cancer Res 2001;61:3853–7.PubMed
17.
Zurück zum Zitat Buck AC, Schirrmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med 2001;42:721–5.PubMed Buck AC, Schirrmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med 2001;42:721–5.PubMed
18.
Zurück zum Zitat Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007;11:291–302.PubMedCrossRef Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007;11:291–302.PubMedCrossRef
19.
Zurück zum Zitat Knoess C, Siegel S, Smith A, Newport D, Richerzhagen N, Winkeler A, et al. Performance evaluation of the microPET R4 PET scanner for rodents. Eur J Nucl Med Mol Imaging 2003;30:737–47.PubMed Knoess C, Siegel S, Smith A, Newport D, Richerzhagen N, Winkeler A, et al. Performance evaluation of the microPET R4 PET scanner for rodents. Eur J Nucl Med Mol Imaging 2003;30:737–47.PubMed
20.
Zurück zum Zitat Phelps ME, editor. PET molecular imaging and its biological applications. New York: Springer; 2004. Phelps ME, editor. PET molecular imaging and its biological applications. New York: Springer; 2004.
21.
Zurück zum Zitat van Kouwen MC, Laverman P, van Krieken JH, Oyen WJ, Jansen JB, Drenth JP. FDG-PET in the detection of early pancreatic cancer in a BOP hamster model. Nucl Med Biol 2005;32:445–50.PubMedCrossRef van Kouwen MC, Laverman P, van Krieken JH, Oyen WJ, Jansen JB, Drenth JP. FDG-PET in the detection of early pancreatic cancer in a BOP hamster model. Nucl Med Biol 2005;32:445–50.PubMedCrossRef
22.
Zurück zum Zitat Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, et al. FDG uptake, Glut-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998;39:1727–35.PubMed Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, et al. FDG uptake, Glut-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998;39:1727–35.PubMed
23.
Zurück zum Zitat von Forstner C, Egberts JH, Ammerpohl O, Niedzielska D, Buchert R, Mikecz P, et al. Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer. J Nucl Med 2008;49:1362–70.CrossRef von Forstner C, Egberts JH, Ammerpohl O, Niedzielska D, Buchert R, Mikecz P, et al. Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer. J Nucl Med 2008;49:1362–70.CrossRef
24.
Zurück zum Zitat Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379–87.PubMedCrossRef Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379–87.PubMedCrossRef
25.
Zurück zum Zitat Hooft L, van der Veldt AA, van Diest PJ, Hoekstra OS, Berkhof J, Teule GJ, et al. [18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumor. J Clin Endocrinol Metab 2005;90:328–34.PubMedCrossRef Hooft L, van der Veldt AA, van Diest PJ, Hoekstra OS, Berkhof J, Teule GJ, et al. [18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumor. J Clin Endocrinol Metab 2005;90:328–34.PubMedCrossRef
26.
Zurück zum Zitat Natsuizaka M, Ozasa M, Darmanin S, Miyamoto M, Kondo S, Kamada S, et al. Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Exp Cell Res 2007;313:3337–48.PubMedCrossRef Natsuizaka M, Ozasa M, Darmanin S, Miyamoto M, Kondo S, Kamada S, et al. Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Exp Cell Res 2007;313:3337–48.PubMedCrossRef
27.
Zurück zum Zitat Yoon DY, Buchler P, Saarikoski ST, Hines OJ, Reber HA, Hankinson O. Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem Biophys Res Commun 2001;288:882–6.PubMedCrossRef Yoon DY, Buchler P, Saarikoski ST, Hines OJ, Reber HA, Hankinson O. Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem Biophys Res Commun 2001;288:882–6.PubMedCrossRef
28.
Zurück zum Zitat Mikuriya K, Kuramitsu Y, Ryozawa S, Fujimoto M, Mori S, Oka M, et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol 2007;30:849–55.PubMed Mikuriya K, Kuramitsu Y, Ryozawa S, Fujimoto M, Mori S, Oka M, et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol 2007;30:849–55.PubMed
29.
Zurück zum Zitat Hingorani SR. New pathways to pancreatic cancer. Cancer Biol Ther 2004;3:170–2.PubMed Hingorani SR. New pathways to pancreatic cancer. Cancer Biol Ther 2004;3:170–2.PubMed
30.
Zurück zum Zitat Schmid RM. Genetic basis of pancreatic cancer. Best Pract Res Clin Gastroenterol 2002;16:421–33.PubMedCrossRef Schmid RM. Genetic basis of pancreatic cancer. Best Pract Res Clin Gastroenterol 2002;16:421–33.PubMedCrossRef
31.
Zurück zum Zitat Tuveson DA, Hingorani SR. Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol 2005;70:65–72.PubMedCrossRef Tuveson DA, Hingorani SR. Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol 2005;70:65–72.PubMedCrossRef
32.
Zurück zum Zitat Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437–50.PubMedCrossRef Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437–50.PubMedCrossRef
33.
Zurück zum Zitat Nitzsche EU, Hoegerle S, Mix M, Brink I, Otte A, Moser E, et al. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nucl Med Mol Imaging 2002;29:237–42.PubMedCrossRef Nitzsche EU, Hoegerle S, Mix M, Brink I, Otte A, Moser E, et al. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nucl Med Mol Imaging 2002;29:237–42.PubMedCrossRef
34.
Zurück zum Zitat Real FX, Cibrián-Uhalte E, Martinelli P. Pancreatic cancer development and progression: remodeling the model. Gastroenterology 2008;135:724–8.PubMedCrossRef Real FX, Cibrián-Uhalte E, Martinelli P. Pancreatic cancer development and progression: remodeling the model. Gastroenterology 2008;135:724–8.PubMedCrossRef
Metadaten
Titel
FDG PET imaging of Ela1-myc mice reveals major biological differences between pancreatic acinar and ductal tumours
verfasst von
Ibane Abasolo
Judit Pujal
Rosa M. Rabanal
Anna Serafin
Pilar Navarro
Olga Millán
Francisco X. Real
Publikationsdatum
01.07.2009
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2009
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-009-1083-3

Weitere Artikel der Ausgabe 7/2009

European Journal of Nuclear Medicine and Molecular Imaging 7/2009 Zur Ausgabe